CN1327843C - 氟马西尼在用于可卡因依赖治疗药物制备中的应用 - Google Patents

氟马西尼在用于可卡因依赖治疗药物制备中的应用 Download PDF

Info

Publication number
CN1327843C
CN1327843C CNB028049411A CN02804941A CN1327843C CN 1327843 C CN1327843 C CN 1327843C CN B028049411 A CNB028049411 A CN B028049411A CN 02804941 A CN02804941 A CN 02804941A CN 1327843 C CN1327843 C CN 1327843C
Authority
CN
China
Prior art keywords
flumazenil
cocaine
treatment
cocaine dependence
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028049411A
Other languages
English (en)
Chinese (zh)
Other versions
CN1491125A (zh
Inventor
胡安何塞·莱加尔达
依瓦涅斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Catasys Inc
Original Assignee
Catasys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catasys Inc filed Critical Catasys Inc
Publication of CN1491125A publication Critical patent/CN1491125A/zh
Application granted granted Critical
Publication of CN1327843C publication Critical patent/CN1327843C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
CNB028049411A 2001-02-15 2002-02-08 氟马西尼在用于可卡因依赖治疗药物制备中的应用 Expired - Fee Related CN1327843C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200100342 2001-02-15
ESP200100342 2001-02-15

Publications (2)

Publication Number Publication Date
CN1491125A CN1491125A (zh) 2004-04-21
CN1327843C true CN1327843C (zh) 2007-07-25

Family

ID=8496743

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028049411A Expired - Fee Related CN1327843C (zh) 2001-02-15 2002-02-08 氟马西尼在用于可卡因依赖治疗药物制备中的应用

Country Status (20)

Country Link
US (2) US7186711B2 (https=)
EP (1) EP1378267B1 (https=)
JP (2) JP4272885B2 (https=)
KR (1) KR100712571B1 (https=)
CN (1) CN1327843C (https=)
AT (1) ATE363923T1 (https=)
AU (1) AU2002231811B2 (https=)
BR (1) BR0207866A (https=)
CA (1) CA2436511C (https=)
CY (1) CY1106845T1 (https=)
DE (1) DE60220512T2 (https=)
DK (1) DK1378267T3 (https=)
ES (1) ES2287255T3 (https=)
IL (1) IL157144A0 (https=)
MX (1) MXPA03007281A (https=)
NZ (1) NZ528164A (https=)
PT (1) PT1378267E (https=)
RU (1) RU2322985C2 (https=)
UA (1) UA79586C2 (https=)
WO (1) WO2002064213A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
CA2436511C (en) * 2001-02-15 2009-08-04 Juan Jose Legarda Ibanez Use of flumazenil to produce a medicament for the treatment of cocaine dependency
JP2008538748A (ja) 2005-04-07 2008-11-06 ハイシアム， インコーポレイテッド 不安、物質乱用及び依存の予防のための改良型方法及び組成物
US7855196B2 (en) 2005-08-22 2010-12-21 Pierre Mainville Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist
ES2289935B1 (es) * 2006-07-14 2008-12-16 Juan Jose Legarda Ibañez Empleo de flumazenilo en la elaboracion de un medicamento para el tratamiento de la patologia depresiva.
US20110034442A1 (en) * 2007-08-08 2011-02-10 Jaun Jose Legarda Ibanez Use and Methods of Use for an Antagonist of the Serotin3 Receptor (5-HT3) and a Selective Modulator of Chloride Channels for the Treatment of Addiction to or Dependence on Medicines/Drugs or Nervous System Disorders
US9396280B2 (en) * 2008-06-23 2016-07-19 Microsoft Technology Licensing, Llc Command driven web site browsing
ES2702848T3 (es) 2011-02-23 2019-03-05 Coeruleus Ltd Complejos de flumazenil, composiciones que los comprenden y usos de los mismos
US9308616B2 (en) 2013-01-21 2016-04-12 Innovative Finishes LLC Refurbished component, electronic device including the same, and method of refurbishing a component of an electronic device
WO2015054730A1 (en) * 2013-10-14 2015-04-23 Palmaya Pty Ltd Compositions and methods of administering same
CN107115359A (zh) * 2016-02-24 2017-09-01 郑恩哲 阻断海洛因或吗啡毒品中毒路径的点滴处方及其应用
EP3661500B1 (en) 2017-07-31 2026-01-07 Novartis AG Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028611A (en) * 1989-06-29 1991-07-02 The Regents Of The University Of Minnesota Treatment for cocaine use
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
US5229120A (en) * 1992-02-05 1993-07-20 Devincent James F Treatment for cocaine abuse
GB9225859D0 (en) * 1992-12-11 1993-02-03 Smithkline Beecham Plc Novel treatment
GB9420010D0 (en) 1994-10-01 1994-11-16 Marck Sharp & Dohme Limited Nucleic acids
EP1133299A1 (en) * 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
EP1125579A3 (en) * 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
CA2436511C (en) 2001-02-15 2009-08-04 Juan Jose Legarda Ibanez Use of flumazenil to produce a medicament for the treatment of cocaine dependency
US6740677B2 (en) 2002-08-19 2004-05-25 Hong Xue Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids

Also Published As

Publication number Publication date
KR100712571B1 (ko) 2007-05-02
HK1061817A1 (en) 2004-10-08
EP1378267B1 (en) 2007-06-06
PT1378267E (pt) 2007-09-11
NZ528164A (en) 2006-03-31
ATE363923T1 (de) 2007-06-15
US20070142364A1 (en) 2007-06-21
DE60220512T2 (de) 2008-02-07
WO2002064213A1 (es) 2002-08-22
DK1378267T3 (da) 2007-10-08
JP2008201799A (ja) 2008-09-04
MXPA03007281A (es) 2005-01-25
DE60220512D1 (de) 2007-07-19
JP4272885B2 (ja) 2009-06-03
AU2002231811B2 (en) 2006-02-16
KR20040010592A (ko) 2004-01-31
CN1491125A (zh) 2004-04-21
CA2436511A1 (en) 2002-08-22
RU2322985C2 (ru) 2008-04-27
US20060122219A1 (en) 2006-06-08
IL157144A0 (en) 2004-02-08
RU2003127718A (ru) 2005-01-27
US7186711B2 (en) 2007-03-06
EP1378267A1 (en) 2004-01-07
BR0207866A (pt) 2004-03-23
JP2004521904A (ja) 2004-07-22
CY1106845T1 (el) 2012-05-23
UA79586C2 (en) 2007-07-10
ES2287255T3 (es) 2007-12-16
CA2436511C (en) 2009-08-04

Similar Documents

Publication Publication Date Title
US20080132492A1 (en) Use of Flumazenil in the Production of a Drug for the Treatment of Alcohol Dependency
JP2008201799A (ja) コカイン依存症治療用薬剤
AU2014249530B2 (en) Use of levocetirizine and montelukast in the treatment of anaphylaxis
JP2004519461A5 (https=)
JP2004521904A5 (https=)
Ganzberg et al. Zaleplon (Sonata) oral sedation for outpatient third molar extraction surgery
KR20080004615A (ko) 알코올 및/또는 흥분성 물질 남용의 치료를 위한 선택적클로라이드 채널 조절제의 용도
HK1061817B (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
AU2006200922A1 (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
AU2006246490B8 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
HK1061661B (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070725